Trial · NCT04731298
Registered outcomes63
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 63
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CXCL9 in Serum | From start of treatment to EoS Visit, up to 34 weeks | Serum concentration of C-X-C Motif Chemokine Ligand 9 (CXCL9) |
| Primary | Primary Graft Failure (GF) | From Hematopoietic stem-cell transplantation (HSCT) [Day 0] up to study termination, approximately 46 weeks | Number of participants with primary graft failure (GF) |
| Primary | Secondary GF | From HSCT (Day 0) up to study termination, approximately 46 weeks | Number of participants with secondary GF |
| Secondary | Free & Total Interferon Gamma (IFNγ) in Serum | From start of treatment to EoS Visit, up to 34 weeks | Serum concentration of free and total Interferon gamma (IFNγ) |
| Secondary | Emapalumab in Serum - Peak | From start of treatment to EoS, up to 34 weeks | Peak emapalumab serum concentration |
| Secondary | Ctrough (Emapalumab) | From start of treatment to EoS, up to 34 weeks | Concentration just before administration |
| Secondary | Exploratory Biomarkers: Ferritin | From HSCT (Day 0) up to study termination, approximately 46 weeks | Ferritin - serum concentration |
| Secondary | ADA and nAbs | From Start of treatment until EoS, up to 34 weeks | Number of participants developing antibodies against emapalumab (antidrug antibodies \[ADA\]) and Neutralizing antibodies (nAb) |
| Secondary | Number of Participants With Mixed Donor Chimerism <10% and <20% | From HSCT (Day 0) up to study termination, approximately 46 weeks | Based on unselected leukocytes and based on sorted T cells |
| Secondary | Number of Participants Receiving Thrombopoietic Agents, Stem Cell Boost, Donor Lymphocyte Infusion (DLI) | From HSCT (Day 0) up to study termination, approximately 46 weeks | |
| Secondary | Number of Participants Receiving a Second Allogeneic HSCT | From HSCT (Day 0) up to study termination, approximately 46 weeks | |
| Secondary | Number of Participants With Poor Graft Function | From HSCT (Day 0) up to study termination, approximately 46 weeks | |
| Secondary | Number of Participants With Event Free Engraftment | From HSCT (Day 0) up to study termination, approximately 46 weeks | defined as absence of GF or graft support |
| Secondary | Number of Participants With Acute and/or Chronic Mild to Severe Graft Versus Host Disease (GvHD) | From HSCT (Day 0) up to study termination, approximately 46 weeks | (grade I to IV) |
| Secondary | Biomarker Levels, in Particular IFNy and CXCL9, as Predictors of Primary and/or Secondary Graft Failure or Acute and/or Chronic GvHD | From HSCT (Day 0) up to study termination, approximately 46 weeks | |
| Secondary | Engraftment Syndrome | From HSCT (Day 0) up to study termination, approximately 46 weeks | Number of participants with engraftment syndrome |
| Secondary | Number of Participants With Endothelial Complications | From HSCT (Day 0) up to study termination, approximately 46 weeks | |
| Secondary | Number of Participants With Relapse, Defined as Cumulative Incidence of Reoccurring Underlying Disease | From HSCT (Day 0) up to study termination, approximately 46 weeks | |
| Secondary | Survival Rate | From HSCT (Day 0) up to study termination, approximately 46 weeks | Number of patients alive at the end of study. |
| Secondary | Change in Body Temperature | From HSCT (Day 0) up to study termination, approximately 46 weeks | Change from baseline in body temperature |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04731298/registered